Minerva Neurosciences (NERV) Profit After Tax (2013 - 2026)
Minerva Neurosciences posted quarterly Profit After Tax of -$125.4 million for Q1 2026, down 3241.47% year-on-year from $4.0 million in Q1 2025, and up 55.79% on a QoQ basis from -$283.7 million in Q4 2025.
Minerva Neurosciences (NERV) has 14 years of Profit After Tax data on file, last reported at -$125.4 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax fell 3241.47% year-over-year to -$125.4 million; the trailing twelve-month figure through Mar 2026 stood at -$415.1 million (down 6736.21% YoY), and the FY2025 full-year result was -$293.4 million, down 20492.68% from the prior year.
- Profit After Tax for Q1 2026 stood at -$125.4 million, up from -$283.7 million in the prior quarter.
- Across five years, Profit After Tax topped out at $22.5 million in Q3 2024 and bottomed at -$283.7 million in Q4 2025.
- The 5-year median for Profit After Tax is -$7.0 million (2023), against an average of -$28.2 million.
- The widest annual swing landed in 2024, when Profit After Tax soared 387.88%; it then slumped 6540.09% in 2025.
- A 5-year view of Profit After Tax shows it stood at -$6.7 million in 2022, then sank by 34.14% to -$9.0 million in 2023, then soared by 52.65% to -$4.3 million in 2024, then plunged by 6540.09% to -$283.7 million in 2025, then surged by 55.79% to -$125.4 million in 2026.
- The last three Profit After Tax figures came in at -$125.4 million (Q1 2026), -$283.7 million (Q4 2025), and -$2.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | -125.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -125.40 Mn |
| Dec 31, 2025 | -283.67 Mn |
| Sep 30, 2025 | -2.74 Mn |
| Jun 30, 2025 | -3.26 Mn |
| Mar 31, 2025 | -3.75 Mn |
| Dec 31, 2024 | -4.27 Mn |
| Sep 30, 2024 | 22.51 Mn |
| Jun 30, 2024 | -8.23 Mn |
| Mar 31, 2024 | -8.57 Mn |
| Dec 31, 2023 | -9.02 Mn |
| Sep 30, 2023 | -7.82 Mn |
| Jun 30, 2023 | -6.19 Mn |
| Mar 31, 2023 | -6.97 Mn |
| Dec 31, 2022 | -6.73 Mn |
| Sep 30, 2022 | -6.90 Mn |
| Jun 30, 2022 | -8.72 Mn |
| Mar 31, 2022 | -9.76 Mn |
| Dec 31, 2021 | -21.31 Mn |
| Sep 30, 2021 | -9.21 Mn |
| Jun 30, 2021 | -10.59 Mn |
| Mar 31, 2021 | -8.80 Mn |
| Dec 31, 2020 | -7.32 Mn |
| Sep 30, 2020 | -8.11 Mn |
| Jun 30, 2020 | 29.53 Mn |
| Mar 31, 2020 | -12.15 Mn |
| Dec 31, 2019 | -29.92 Mn |
| Sep 30, 2019 | -13.96 Mn |
| Jun 30, 2019 | -12.48 Mn |
| Mar 31, 2019 | -15.83 Mn |
| Dec 31, 2018 | -13.20 Mn |
| Sep 30, 2018 | -12.02 Mn |
| Jun 30, 2018 | -12.53 Mn |
| Mar 31, 2018 | -12.42 Mn |
| Dec 31, 2017 | 162,000.00 |
| Sep 30, 2017 | -11.26 Mn |
| Jun 30, 2017 | -9.78 Mn |
| Mar 31, 2017 | -10.65 Mn |
| Dec 31, 2016 | -9.40 Mn |
| Sep 30, 2016 | -8.42 Mn |
| Jun 30, 2016 | -5.21 Mn |
| Mar 31, 2016 | -8.00 Mn |
| Dec 31, 2015 | -8.44 Mn |
| Sep 30, 2015 | -5.94 Mn |
| Jun 30, 2015 | -6.61 Mn |
| Mar 31, 2015 | -6.09 Mn |
| Dec 31, 2014 | -7.44 Mn |
| Sep 30, 2014 | -27.16 Mn |
| Jun 30, 2014 | -19.37 Mn |
| Mar 31, 2014 | -2.94 Mn |
| Dec 31, 2013 | -2.13 Mn |
| Sep 30, 2013 | -488,000.00 |
| Jun 30, 2013 | -376,000.00 |